| scholarly article | Q13442814 |
| P50 | author | Emily Somers | Q42611546 |
| P2093 | author name string | Hemal Mehta | |
| Mariana J Kaplan | |||
| Seth Thacker | |||
| Franck J Barrat | |||
| W Joseph McCune | |||
| Todd Dodick | |||
| Michael F Denny | |||
| P2860 | cites work | Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells | Q22010519 |
| IL-4 and IL-13 induce protection of porcine endothelial cells from killing by human complement and from apoptosis through activation of a phosphatidylinositide 3-kinase/Akt pathway | Q24309128 | ||
| Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration | Q28207902 | ||
| The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells | Q28214312 | ||
| Circulating endothelial progenitor cells and cardiovascular outcomes | Q28271167 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Interferon and granulopoiesis signatures in systemic lupus erythematosus blood | Q29615064 | ||
| Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells | Q33194273 | ||
| Interferon alpha-2a for proliferative diabetic retinopathy after complete laser panretinal photocoagulation treatment. | Q33197220 | ||
| Cytokines and vascular permeability: an in vitro study on human endothelial cells in relation to tumor necrosis factor-alpha-primed peripheral blood mononuclear cells | Q33233014 | ||
| Interferon alfa-2a therapy for life-threatening hemangiomas of infancy | Q33359336 | ||
| Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 | ||
| IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells | Q34290178 | ||
| Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis | Q34363721 | ||
| Vascular progenitors: from biology to treatment | Q34536546 | ||
| Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization | Q35111623 | ||
| Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism | Q35220307 | ||
| Interferon-alpha in systemic lupus erythematosus | Q35864686 | ||
| Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus | Q35954549 | ||
| Alpha-interferon and its effects on signalling pathways within cells | Q35974159 | ||
| Role of monocytes and macrophages in angiogenesis | Q35992873 | ||
| Treatments of AIDS-related Kaposi's sarcoma | Q36046535 | ||
| Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus | Q36403653 | ||
| Type I interferon in systemic lupus erythematosus and other autoimmune diseases | Q36595839 | ||
| Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon | Q37220486 | ||
| Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies | Q40273508 | ||
| Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. | Q40468150 | ||
| SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. | Q40622515 | ||
| IFN-α Skews Monocyte Differentiation into Toll-Like Receptor 7-Expressing Dendritic Cells with Potent Functional Activities | Q40633237 | ||
| Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach | Q40888776 | ||
| Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus | Q41608189 | ||
| Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand | Q42767299 | ||
| Mobilization of endothelial progenitor cells in patients with acute myocardial infarction | Q43636896 | ||
| Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus | Q43808480 | ||
| Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. | Q44441787 | ||
| Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. | Q47398233 | ||
| Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure | Q47449596 | ||
| Interferon-alpha primes macrophages for lipopolysaccharide-induced apoptosis | Q50141940 | ||
| Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. | Q51345347 | ||
| Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. | Q52094951 | ||
| Aberrant phenotype and function of myeloid dendritic cells in systemic lupus erythematosus. | Q53592228 | ||
| Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. | Q53718320 | ||
| Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells | Q72709578 | ||
| IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences | Q73881302 | ||
| Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures | Q78570627 | ||
| Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha | Q79372327 | ||
| Are indoleamine-2,3-dioxygenase producing human dendritic cells a tool for suppression of allogeneic T-cell responses? | Q79820468 | ||
| Stat3 mediates interleukin-6 [correction of interelukin-6] inhibition of human endothelial nitric-oxide synthase expression | Q80057578 | ||
| Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus | Q81129128 | ||
| Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis | Q81252239 | ||
| Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo | Q83182773 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vasculogenesis | Q1424593 |
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 2907-2915 | |
| P577 | publication date | 2007-07-16 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis | |
| P478 | volume | 110 |
| Q53245134 | A 26-year-old white man with a systemic lupus erythematosus flare and acute multiorgan ischemia: Vasculitis or thrombosis? |
| Q38537618 | A Plasmacytoid Dendritic Cells-Type I Interferon Axis Is Critically Implicated in the Pathogenesis of Systemic Lupus Erythematosus |
| Q34089816 | A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs |
| Q37658524 | Accelerated atherosclerosis in SLE: mechanisms and prevention approaches |
| Q26820245 | Accelerated atherosclerosis in patients with SLE--mechanisms and management |
| Q34170097 | Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches |
| Q55402266 | Accelerated model of lupus autoimmunity and vasculopathy driven by toll-like receptor 7/9 imbalance. |
| Q41641093 | Acetylation impacts Fli-1-driven regulation of granulocyte colony stimulating factor |
| Q37776830 | Activation of the type I interferon pathway in primary Sjogren’s syndrome |
| Q34240254 | Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes |
| Q34055844 | An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage |
| Q36396428 | Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. |
| Q37994309 | Biomarkers for systemic lupus erythematosus |
| Q37145684 | Cardiometabolic risk in psoriasis: differential effects of biologic agents |
| Q27016554 | Cardiovascular disease in lupus: insights and updates |
| Q35214718 | Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions |
| Q83233981 | Circulating endothelial progenitor cells are reduced in SLE in the absence of coronary artery calcification |
| Q35617573 | Cytokine disturbances in systemic lupus erythematosus |
| Q42141284 | Cytokine-induced monocyte characteristics in SLE |
| Q26782454 | Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus Erythematosus |
| Q47684869 | Decidual T Cells Exhibit a Highly Differentiated Phenotype and Demonstrate Potential Fetal Specificity and a Strong Transcriptional Response to IFN. |
| Q51182420 | Decreased circulating endothelial progenitor cells as an early risk factor of subclinical atherosclerosis in systemic lupus erythematosus. |
| Q38078691 | Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases |
| Q34788956 | Determinants of vascular function in patients with chronic gout |
| Q37453947 | Developments in the clinical understanding of lupus |
| Q42726421 | Dysfunction of endothelial progenitor cells is associated with the type I IFN pathway in patients with polymyositis and dermatomyositis |
| Q54295685 | Editorial: "Interfering" with preeclampsia. |
| Q43041708 | Effects of prasterone (dehydroepiandrosterone) on markers of cardiovascular risk and bone turnover in premenopausal women with systemic lupus erythematosus: a pilot study |
| Q39264755 | Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation |
| Q90455731 | Endothelial Progenitor Cells: New Targets for Therapeutics for Inflammatory Conditions With High Cardiovascular Risk |
| Q46061403 | Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus. |
| Q37478067 | Endothelial progenitor cell dysfunction in rheumatic disease |
| Q35901110 | Endothelial progenitor cell phenotype and function are impaired in childhood-onset systemic lupus erythematosus. |
| Q35774189 | Endothelial progenitor cells in cardiovascular disease and chronic inflammation: from biomarker to therapeutic agent |
| Q36084953 | Endothelial progenitor cells: a new player in lupus? |
| Q37624581 | Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases |
| Q39586997 | Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome |
| Q90871287 | Endothelium structure and function in kidney health and disease |
| Q37625812 | Expression of an anti-RNA autoantibody in a mouse model of SLE increases neutrophil and monocyte numbers as well as IFN-I expression |
| Q38135706 | Future prospects in biologic therapy for systemic lupus erythematosus |
| Q42703913 | How does interferon-α insult the vasculature? Let me count the ways |
| Q47806004 | IFN-α Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus. |
| Q37500133 | IFNα serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients |
| Q37699812 | Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus. |
| Q35566819 | Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus |
| Q64946853 | Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients. |
| Q93188187 | Interferon pathway in SLE: one key to unlocking the mystery of the disease |
| Q35236547 | Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia |
| Q39600465 | Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus |
| Q35661943 | Interleukin 10 hampers endothelial cell differentiation and enhances the effects of interferon α on lupus endothelial cell progenitors |
| Q47439880 | JAK inhibition as a therapeutic strategy for immune and inflammatory diseases |
| Q48556502 | JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. |
| Q92550885 | L-sepiapterin restores SLE serum-induced markers of endothelial function in endothelial cells |
| Q91721378 | Lupus-associated endogenous retroviral LTR polymorphism and epigenetic imprinting promote HRES-1/RAB4 expression and mTOR activation |
| Q35152132 | Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells |
| Q35620995 | MAb therapy against the IFN-α/β receptor subunit 1 stimulates arteriogenesis in a murine hindlimb ischaemia model without enhancing atherosclerotic burden |
| Q33730536 | Management of cardiovascular complications in systemic lupus erythematosus |
| Q37428743 | Management of cardiovascular disease risk in chronic inflammatory disorders |
| Q34343906 | Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus |
| Q37633711 | Milk fat globule-EGF factor 8 suppresses the aberrant immune response of systemic lupus erythematosus-derived neutrophils and associated tissue damage |
| Q36548651 | Modulation of Endothelial Injury Biomarkers by Traditional Chinese Medicine LC in Systemic Lupus Erythematosus Patients Receiving Standard Treatments |
| Q34292033 | Monocyte activation from interferon-α in HIV infection increases acetylated LDL uptake and ROS production |
| Q52726621 | Mycophenolic acid induces senescence of vascular precursor cells. |
| Q36252681 | Nailfold Capillary Abnormalities in Primary Open-Angle Glaucoma: A Multisite Study. |
| Q34084599 | Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2 |
| Q55185377 | Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. |
| Q27000384 | Neutrophils in the pathogenesis and manifestations of SLE |
| Q24612339 | Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model |
| Q35145964 | Opposing effects of monomeric and pentameric C-reactive protein on endothelial progenitor cells |
| Q44937839 | Osteoprotegerin causes apoptosis of endothelial progenitor cells by induction of oxidative stress |
| Q21195364 | Overview of the biology of type I interferons |
| Q36966870 | Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus |
| Q36064574 | Plasmacytoid dendritic cells in atherosclerosis |
| Q37730992 | Potential role of IFNα in adult lupus |
| Q34635470 | Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine |
| Q33387473 | Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study |
| Q37573524 | Premature vascular damage in systemic lupus erythematosus |
| Q37549027 | Premature vascular damage in systemic lupus erythematosus: an imbalance of damage and repair? |
| Q33704086 | Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound |
| Q52316454 | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. |
| Q55383884 | Report of the inaugural Interferon Research Summit: interferon in inflammatory diseases. |
| Q33727015 | Rheumatic autoimmune diseases in women and midlife health |
| Q35920339 | Role of interferon alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase-related mechanisms |
| Q90432999 | Role of microRNAs in the Development of Cardiovascular Disease in Systemic Autoimmune Disorders |
| Q37033345 | Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention |
| Q38758892 | The Role of Toll-Like Receptors in Autoimmune Diseases through Failure of the Self-Recognition Mechanism. |
| Q82092557 | The cardiovascular threat of lupus |
| Q30497355 | The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction |
| Q35191332 | The effect of acute exposure to coarse particulate matter air pollution in a rural location on circulating endothelial progenitor cells: results from a randomized controlled study |
| Q33588015 | The effect of type 1 IFN on human aortic endothelial cell function in vitro: relevance to systemic lupus erythematosus |
| Q37206876 | The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus |
| Q34127758 | The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis? |
| Q35169351 | The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus |
| Q52725381 | The non-haemostatic role of platelets in systemic lupus erythematosus. |
| Q37395321 | The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. |
| Q37683553 | The role IL-1 in tumor-mediated angiogenesis |
| Q37308042 | The search for lupus biomarkers |
| Q35514368 | The type I interferon system in the etiopathogenesis of autoimmune diseases |
| Q37541469 | Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. |
| Q34015433 | Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis |
| Q40513608 | Transcriptome Sequencing to Identify Transcription Factor Regulatory Network and Alternative Splicing in Endothelial Cells Under VEGF Stimulation |
| Q37570669 | Transplantation of endothelial progenitor cells as therapeutics for cardiovascular diseases |
| Q38335622 | Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine. |
| Q37713730 | Type I interferon therapy and its role in autoimmunity |
| Q28293186 | Type I interferon: friend or foe? |
| Q34273836 | Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients |
| Q36139902 | Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis |
| Q38844782 | Update on cardiovascular disease in lupus |
| Q38693342 | Visfatin induces the apoptosis of endothelial progenitor cells via the induction of pro-inflammatory mediators through the NF-κB pathway |
| Q36634362 | Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus |
Search more.